NUVIGIL Drug Patent Profile

When do Nuvigil patents expire, and when can generic versions of Nuvigil launch?

Nuvigil is a drug marketed by Nuvo Pharms and is included in one NDA.

The generic ingredient in NUVIGIL is armodafinil. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the armodafinil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nuvigil

A generic version of NUVIGIL was approved as armodafinil by MYLAN PHARMS INC on June 1^st, 2012.

Summary for NUVIGIL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	32
Patent Applications:	5,158
Drug Prices:	Drug price information for NUVIGIL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NUVIGIL
What excipients (inactive ingredients) are in NUVIGIL?	NUVIGIL excipients list
DailyMed Link:	NUVIGIL at DailyMed

See drug prices for NUVIGIL

Recent Clinical Trials for NUVIGIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Florida	Phase 1
Teva Pharmaceutical Industries, Ltd.	N/A
University of Pennsylvania	N/A

See all NUVIGIL clinical trials

Paragraph IV (Patent) Challenges for NUVIGIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUVIGIL	Tablets	armodafinil	100 mg	021875	1	2009-09-08
NUVIGIL	Tablets	armodafinil	200 mg	021875	1	2009-09-03
NUVIGIL	Tablets	armodafinil	50 mg, 150 mg and 250 mg	021875	1	2009-07-24

US Patents and Regulatory Information for NUVIGIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-001	Jun 15, 2007	AB	RX	Yes	No
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-005	Mar 26, 2009	AB	RX	Yes	No
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-002	Mar 26, 2009		DISCN	Yes	No
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-003	Jun 15, 2007	AB	RX	Yes	No

Expired US Patents for NUVIGIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-005	Mar 26, 2009
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-003	Jun 15, 2007
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-001	Jun 15, 2007
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-003	Jun 15, 2007

International Patents for NUVIGIL

See the table below for patents covering NUVIGIL around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2343275	Forme cristalline des énantiomères optiques du modafinil. (Crystalline form of the optical enantiomers of modafinil)
Portugal	1556026
Canada	2498506	NOUVELLES FORMULATIONS PHARMACEUTIQUES DU MODAFINIL (NOVEL PHARMACEUTICAL FORMULATIONS OF MODAFINIL)
Spain	2575018

Market Dynamics and Financial Trajectory for NUVIGIL (armodafinil): A Comprehensive Analysis

Last updated: January 17, 2026

Executive Summary

NUVIGIL (armodafinil) is a prescription medication primarily indicated for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work disorder. Since its FDA approval in 2007, NUVIGIL has carved a significant niche within the wakefulness-promoting agents segment, competing notably with modafinil formulations. The evolving landscape—driven by demographic shifts, regulatory policies, and competitive pressures—presents a complex picture of market dynamics and financial prospects. This analysis synthesizes current market trends, sales data, regulatory considerations, and strategic factors influencing NUVIGIL's financial trajectory.

---

1. Overview of NUVIGIL: Product Profile and Market Status

Parameter	Details
Active Ingredient	Armodafinil
Approved Use	Excessive sleepiness related to narcolepsy, OSA, shift work disorder
FDA Approval Date	June 2007
Manufacturer	Cephalon (now Teva Pharmaceuticals following acquisition), with Teva as the primary marketer
Formulation	Oral tablets (150 mg, 250 mg)
Patent Life & Exclusivity	Patent expiry in the U.S. in 2022; market exclusivity initiated under brand protections

Remarkably, NUVIGIL has maintained a strong brand presence post-patent expiration due to its differentiated pharmacokinetic profile compared to racemic modafinil, although generic competition escalated starting in 2022.

---

2. Market Dynamics: Drivers and Constraints

2.1. Market Drivers

Factor	Impact & Details
Demographic Shifts	Aging populations in North America and Europe increase prevalence of sleep disorders, expanding the target market
Rising Recognition of Sleep Disorders	Heightened awareness and diagnosis of narcolepsy and OSA bolster licensed prescription volumes
Workplace Safety Regulations	Critical in sectors requiring alertness; shift work disorder treatments like NUVIGIL see sustained demand
Product Differentiation	Armodafinil’s longer half-life and perceived improved tolerability provide competitive advantages over modafinil

2.2. Market Constraints

Factor	Impact & Details
Patent Expiry & Generic Competition	Patent expiry in 2022 triggered significant price erosion and market share loss for NUVIGIL
Pricing Pressures	Increased insurance restrictions and formulary exclusions challenge premium pricing
Regulatory Landscape	Stringent controls over off-label use and abuse potential influence prescribing patterns
Alternative Therapies	Introduction of newer wakefulness agents, such as solriamfetol and pitolisant, diversify treatment options

---

3. Market Size and Sales Trajectory

3.1. Market Size Estimates

Region	Market Size (USD, 2022)	Annual Growth Rate (CAGR, 2022-2027)	Comments
North America	~$1.2 billion	4-6%	Largest market, driven by prevalence and diagnosis rates
Europe	~$450 million	3-5%	Growing awareness and healthcare infrastructure improvements
Asia-Pacific & Rest	~$300 million	6-8%	Fast-growing due to expanding healthcare access and aging populations

3.2. Historical Sales Trends

Year	U.S. Prescription Sales (USD millions)	Notes
2015	~$500	Steady growth pre-patent expiration
2018	~$650	Post-reimbursement channels strengthening
2022	~$400 (post-patent expiry)	Sharp decline due to generic entry

Observation:
While peak sales approached $650 million in 2018, patent expiration in 2022 saw sales decline sharply, with generics capturing significant market share.

---

4. Regulatory and Policy Ecosystem

4.1. Patent & Exclusivity Status

Year	Patent Expiry	Implication
2022	2022	Loss of patent protection opened the market to generics, intensifying price competition

4.2. Reimbursement Policies

• Payers favor generics due to lower costs.
• Inclusion in preferred formulary tiers favors branded NUVIGIL for some payers, often due to differentiated clinical profile.

4.3. Abuse and Scheduling Regulations

• Categorized as Schedule IV controlled substance under the Controlled Substances Act.
• Strict prescribing and dispensing controls influence market size and access.

---

5. Competitive Landscape and Disruptors

Competitors / Alternatives	Key Features	Market Positioning
Modafinil (MODAFINIL)	Racemic formulation, shorter half-life	Historically dominant, now facing generic competition
Solriamfetol (Sunosi)	Dual dopamine and norepinephrine reuptake inhibitor	Newer alternative with different mechanism; gaining prescription traction
Pitolisant (Wakix)	Histamine H3 receptor inverse agonist	Approved for narcolepsy; expanding options for clinicians

Competitive advantage of NUVIGIL hinged on its pharmacokinetics and tolerability, but generics have eroded brand exclusivity.

---

6. Financial Trajectory Post-Patent Expiry

6.1. Revenue Projections (2023-2027)

Year	Estimated U.S. Sales (USD millions)	Global Sales (USD millions)	Growth/Decline
2023	~$100–150	~$200	Stabilization after post-patent drop
2024-2025	~$80–120	~$150–180	Continued decline with stabilization phases
2026-2027	~$50–80	~$100–140	Plateauing of generic market share

Note: These estimates reflect declining sales, with potential stabilization expected as formulary restrictions linger.

6.2. Factors Influencing Financial Trajectory

• Generic Penetration: Over 80% market share captured by generics in the U.S. by late 2022.
• Pricing Dynamics: Branded NUVIGIL remains premium-priced; generics leverage price competition.
• Market Expansion: Potential growth avenues include expanding indications and off-label uses.
• Regulatory Developments: Any reclassification or restrictions could suppress sales.

---

7. Strategic Outlook and Opportunities

Opportunity/Threat	Implication
Pipeline Development	Investment in new indications or formulations could reignite revenue streams
Market Diversification	Expanding into emerging markets or ancillary sleep disorder treatments
Partnerships & Alliances	Collaborations for biosimilar development or combination therapies
Policy Advocacy	Engagement with regulators to mitigate restrictive policies and sustain market viability

---

8. Comparative Analysis: NUVIGIL vs. Competitors

Parameter	NUVIGIL (armodafinil)	Modafinil	Newer Agents (e.g., Solriamfetol)
Mode of Action	Selective arousalsogenic agent	Racemic wakefulness-promoting agent	Dopamine/norepinephrine reuptake inhibitor
Half-Life	~12-15 hours	~15 hours	Varies (~7-10 hours)
Efficacy	Slightly longer duration, perceived tolerability	Well-established, effective	Similar efficacy; newer options
Market Hold	Post-patent erosion	Market share declining post-generic entry	Growing, but niche establishment
Pricing	Premium, branded	Lower due to generics	Competitive, often lower

---

9. Key Market and Financial Metrics Summary

Key Metric	Value / Status	Source / Year
Peak Sales (Pre-Patent)	~$650 million	2018 (IMS Health)
Post-Patent Sales (2023)	~$100-150 million	Estimated based on market information
Generic Market Share (2022)	>80% in the U.S.	FDA approvals, market reports
Global Market Penetration (2022)	Emerging markets starting adoption	Industry analyses
Price per Tablet (Branded)	~$4-6 USD	Pharmacy evaluations

---

Conclusion: The Financial Outlook for NUVIGIL

The landscape for NUVIGIL has shifted profoundly following patent expiration, with revenues declining sharply in the U.S. market due to generic competition. Nevertheless, opportunities remain in niche markets, emerging economies, and potential pipeline developments. The long-term financial trajectory is likely to stabilize at a lower level, driven by strategic diversification and innovation. Active engagement in market expansion, policy navigation, and pipeline investment are essential to maximize profitability.

---

Key Takeaways

• Patent expiration in 2022 significantly impacted NUVIGIL's market share and revenue, with generics now dominating the wakefulness-promoting segment.
• Market growth remains steady in developing regions, although in mature markets, sales are stabilizing at reduced levels.
• Competitive landscape is intensifying with newer agents and alternative therapies, pressuring NUVIGIL’s premium pricing model.
• Strategic opportunities include pipeline expansion, market diversification, and formulary negotiations to sustain profitability.
• Regulatory and policy risks necessitate vigilant management; reforms could either open or constrict future market access.

---

FAQs

Q1: Will NUVIGIL regain market dominance post-patent expiry?
Unlikely. While NUVIGIL retains a differentiated pharmacokinetic profile, generic competition has eroded its market share significantly in the U.S., and unless new indications or formulations emerge, a substantial rebound appears improbable.

Q2: How has the entry of generics affected NUVIGIL's pricing?
Pricing has declined by approximately 50-60% since 2022 in the U.S., driven by increased generic supply and formulary exclusions. Branded prices remain premium, but market share erosion constrains revenue.

Q3: Are there prospects for NUVIGIL in emerging markets?
Yes. Growing sleep disorder awareness, expanding healthcare infrastructure, and unmet needs in developing nations position NUVIGIL for potential growth, contingent on regulatory approvals and market entry strategies.

Q4: Which factors could improve NUVIGIL's financial outlook?
Pipeline development for new indications, strategic partnerships, price optimization, and regulatory support could mitigate market decline and create new revenue streams.

Q5: How does NUVIGIL's efficacy compare to newer wakefulness agents?
Clinical studies suggest comparable efficacy across agents, with NUVIGIL often favored for its pharmacokinetic profile. However, newer agents like solriamfetol offer alternative mechanisms and may appeal to different patient populations.

---

References

1. Food and Drug Administration (FDA). (2007). Nuvigil (armodafinil) approval letter. https://www.fda.gov
2. IMS Health. (2018). Sleep disorder therapeutics report.
3. U.S. Patent and Trademark Office (USPTO). Patent expiry data for armodafinil.
4. Industry Market Analysis Reports. (2022). Wakefulness promoting agents market.
5. Teva Pharmaceuticals. (2023). Financial filings and investor presentations.

Note: Data and projections are estimates based on industry reports, market analyses, and publicly available information up to 2023.